TUMOUR NECROSIS FACTOR ALPHA GENE PROMOTER POLYMORPHISM IN PATIENTS WITH SCHIZOPHRENIA IN A KENYAN POPULATION

Abstract

Abstract Aim Tumour necrosis factor alpha (TNF-α) promoter single nucleotide polymorphisms (SNPs) have been reported to play pathological roles in schizophrenia with contradicting findings in several studies. The status of TNF-α SNPs remains unknown in our population. Therefore, this study sought to determine the association of TNF-α gene promoter single nucleotide polymorphisms -308A/G (rs 1800629) and -1031C/T (rs 1799964) in patients with schizophrenia at MTRH, Kenya. Methods A case-control study at MTRH included 82 schizophrenia patients and 82 age and sex-matched healthy controls. Participants’ demographic data were collected using an interviewer-administered questionnaire, and DNA was extracted from saliva samples for TNF-α SNP genotyping using the Allelic Discrimination Assay®. Results There were no statistically significant differences in genotype distribution and allele frequencies between cases and controls for -308A/G and -1031C/T polymorphisms (p = 0.261) and (p = 0.678) respectively. The genotype associations with schizophrenia were: at - 308(rs1800629), A/G had OR 1.67, 95% CI (0.88-3.16) p=0.114. At -1031(rs1799964), genotype C/C and C/T, had OR 0.66, 95% CI (0.22-1.97) p=0.455 and OR 0.75, 95% CI (0.48-1.18) p=0.255 while a combination of C/T-C/C, had OR 0.743, 95% CI (0.40-1.38) p=0.346. Conclusion These results demonstrate that SNPs in the TNF-α promoter region at the studied loci are unrelated to schizophrenia. These SNPs may not serve as useful biomarkers for diagnosis or targeted therapy. Further analysis of these SNPs focusing on specific schizophrenia symptoms, rather than the entire syndrome, may be needed.